Affiliation:
1. DAAN Gene Co., Ltd. of Sun Yat-Sen University, 19 Xiangshan Road, Science Park, High & New Technology Development District, Guangzhou, Guangdong, China
Abstract
Background:
CYP2C19 is an important genetic factor modulating clopidogrel dose
requirement.
Objective:
Therefore, a simple and economic genotyping method for predicting the clopidogrel
dose of patients would be useful in clinical applications.
Methods:
In this study, the MGB blocker ARMS real-time PCR contained two forward primers,
two MGB blockers and a common reverse primer have been used for CYP2C19*2, *3 and *17
substitutions.
Results:
Results showed that heterozygotes and homozygotes of CYP2C19*2, *3 and *17 could be
distinguished by the MGB blocker ARMS real-time PCR successfully. In the Chinese population,
patients with allele frequencies of CYP2C19*2, *3, and *17 are 18.43%, 3.03% and 0.76%,
respectively.
Conclusion:
This study indicates that the MGB blocker ARMS real-time PCR will be a simple,
economical method for the rapid detection of SNPs in CYP2C19.
Funder
Science and Technology Projects of Guangzhou
Publisher
Bentham Science Publishers Ltd.
Subject
Computational Mathematics,Genetics,Molecular Biology,Biochemistry
Reference20 articles.
1. Uchiyama S. Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment.
2. Plosker GL, Lyseng-Williamson KA. Clopidogrel: a review of its use in the prevention of thrombosis.
3. Singh M, Thapa B, Arora R. Clopidogrel pharmacogenetics and its clinical implications.
4. Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.
5. Osnabrugge RL, Head SJ, Zijlstra F. A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献